227 related articles for article (PubMed ID: 33707412)
1. CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes.
Bezerra ED; Lasho TL; Finke CM; Saliba AN; Elliott MA; Pardanani AD; Gangat N; Mangaonkar AA; Ketterling RP; Tefferi A; Solary E; Patnaik MM
Blood Cancer J; 2021 Mar; 11(3):54. PubMed ID: 33707412
[No Abstract] [Full Text] [Related]
2. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
4. CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature.
Guastafierro V; Ubezio M; Manes N; Milanesi C; Della Porta M; Bonometti A
Leuk Lymphoma; 2023 Sep; 64(9):1566-1573. PubMed ID: 37395413
[TBL] [Abstract][Full Text] [Related]
5. T618I-Mutated Colony Stimulating Factor 3 Receptor in Chronic Neutrophilic Leukemia and Chronic Myelomonocytic Leukemia Patients who Underwent Allogeneic Stem Cell Transplantation.
Lee SE; Jo I; Jang W; Kim Y; Han K; Kim M
Ann Lab Med; 2015 May; 35(3):376-8. PubMed ID: 25932451
[No Abstract] [Full Text] [Related]
6.
Kwon A; Ibrahim I; Le T; Jaso JM; Weinberg O; Fuda F; Chen W
Leuk Res Rep; 2022; 17():100323. PubMed ID: 35586707
[TBL] [Abstract][Full Text] [Related]
7. Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
Kim HY; Lee KO; Park S; Jang JH; Jung CW; Kim SH; Kim HJ
Ann Lab Med; 2018 Nov; 38(6):495-502. PubMed ID: 30027691
[TBL] [Abstract][Full Text] [Related]
8. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
Qian Y; Chen Y; Li X
Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
[TBL] [Abstract][Full Text] [Related]
9. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
Itzykson R; Kosmider O; Renneville A; Gelsi-Boyer V; Meggendorfer M; Morabito M; Berthon C; Adès L; Fenaux P; Beyne-Rauzy O; Vey N; Braun T; Haferlach T; Dreyfus F; Cross NC; Preudhomme C; Bernard OA; Fontenay M; Vainchenker W; Schnittger S; Birnbaum D; Droin N; Solary E
J Clin Oncol; 2013 Jul; 31(19):2428-36. PubMed ID: 23690417
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
[TBL] [Abstract][Full Text] [Related]
11. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract][Full Text] [Related]
12. Germline
Bochicchio MT; Micucci G; Asioli S; Ghetti M; Simonetti G; Lucchesi A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003211
[TBL] [Abstract][Full Text] [Related]
13. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
Lin Y; Zheng Y; Wang ZC; Wang SY
Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
[TBL] [Abstract][Full Text] [Related]
15. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.
Sallman DA; Komrokji R; Cluzeau T; Vaupel C; Al Ali NH; Lancet J; Hall J; List A; Padron E; Song J
Blood Cancer J; 2017 Nov; 7(12):633. PubMed ID: 29176559
[No Abstract] [Full Text] [Related]
16. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
[TBL] [Abstract][Full Text] [Related]
17. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
18. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.
Pardanani A; Lasho TL; Laborde RR; Elliott M; Hanson CA; Knudson RA; Ketterling RP; Maxson JE; Tyner JW; Tefferi A
Leukemia; 2013 Sep; 27(9):1870-3. PubMed ID: 23604229
[TBL] [Abstract][Full Text] [Related]
19. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811
[TBL] [Abstract][Full Text] [Related]
20. Moving towards a uniform risk stratification system in CMML - How far are we?
Chan O; Padron E
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101131. PubMed ID: 32460982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
